Cellectis patent surprises biopharma, could block CRISPR
A patent issued to French biotech Cellectis threatens to block gene editing tools currently in use by several big pharma and service companies.
Archives for January 9, 2015
Horizon buys Haplogen chromosome tech for ‘10x’ faster cell production
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
CAR-T race heats up with flurry of new deals
The hype around developing new CAR-T (Chimeric Antigen Receptor transduced T) cell therapies, which can fight cancers by modifying patients’ immune cells, seemed to hit a new high this week, with two partnerships and an acquisition.